Practical considerations of beta-blockade in the management of the post-myocardial infarction patient.

[1]  G. Oster,et al.  Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. , 2005, International journal of cardiology.

[2]  P. Raskin,et al.  Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial , 2005 .

[3]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[4]  K. Sliwa,et al.  Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. , 2004, Journal of the American College of Cardiology.

[5]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[6]  J. Rouleau,et al.  Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. , 2004, Journal of the American College of Cardiology.

[7]  P. Poole‐Wilson,et al.  1001-26 Exchange of beta-blocking therapy in heart failure patients. Experiences from the post study phase of COMET (the carvedilol or metoprolol European trial) , 2004 .

[8]  G. Oster,et al.  821-5 Risks of death and hospitalization in heart failure patients receiving carvedilol versus metoprolol tartrate: A retrospective claims-based study , 2004 .

[9]  A. Cohen-Solal,et al.  Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes: Observations From the Global Registry of Acute Coronary Events (GRACE) , 2004, Circulation.

[10]  M. Packer.  Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial , 2003 .

[11]  W. Abraham.  Switching between beta blockers in heart failure patients: rationale and practical considerations. , 2003, Congestive heart failure.

[12]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[13]  J. Rouleau,et al.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. , 2003, JAMA.

[14]  S. Jencks,et al.  Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. , 2003, JAMA.

[15]  C. Cannon,et al.  Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. , 2003, Reviews in cardiovascular medicine.

[16]  J. Sackner-Bernstein.  New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. , 2003, Reviews in cardiovascular medicine.

[17]  L. Parsons,et al.  Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). , 2002, Journal of the American College of Cardiology.

[18]  G. Nickenig,et al.  Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[19]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[20]  V. Fuster,et al.  AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.

[21]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[22]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[23]  L. Goldman,et al.  Health and Economic Benefits of Increased β-Blocker Use Following Myocardial Infarction , 2000 .

[24]  J S Alpert,et al.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.

[25]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[26]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[27]  E. Bates,et al.  The enduring value of Killip classification. , 1999, American heart journal.

[28]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[29]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[30]  A. Camm,et al.  Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. , 1998, The American journal of cardiology.

[31]  J. Gore,et al.  Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. , 1998, American heart journal.

[32]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[33]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[34]  B. McNeil,et al.  Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. , 1994, Journal of the American College of Cardiology.

[35]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .

[36]  J. Willerson,et al.  The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group. , 1987, European heart journal.

[37]  R. Byington,et al.  Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.

[38]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[39]  Johan Herlitz,et al.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. , 1985, European heart journal.

[40]  J. Herlitz.  Metoprolol in acute myocardial infarction. Patients and methods. The MIAMI Trial Research Group. , 1985, The American journal of cardiology.

[41]  K. Swedberg,et al.  The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. , 1983, Circulation.

[42]  Å. Hjalmarson.  METOPROLOL IN ACUTE MYOCARDIAL INFARCTION , 1982, The Lancet.

[43]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[44]  T. Killip,et al.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. , 1967, The American journal of cardiology.